Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Buy AbbVie, stock still worth owning even as Humira fades, Barron's says » 08:41
12/03/22
12/03
08:41
12/03/22
08:41
ABBV

AbbVie

$163.65 /

+2.03 (+1.26%)

AbbVie's blockbuster…

AbbVie's blockbuster drug Humira faces patent expirations, but there's a lot more to it than the immunosuppressive, Teresa Rivas writes in this week's edition of Barron's. The company has profitable products that have begun to fill the gap left by Humira's decline. Investors who preferred to wait out the transition from Humira may have erred -- AbbVie stock is up by more than 19%, to a recent $162, so far in 2022. Moreover, the stock looks cheap and has a handsome dividend yield. It's worth owning-now, the author argues. Reference Link

ShowHide Related Items >><<
ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

11/17/22 Credit Suisse
AbbVie initiated with an Outperform at Credit Suisse
11/08/22 Societe Generale
AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
11/08/22 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
10/28/22 Piper Sandler
Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

ABBV AbbVie
$163.65 /

+2.03 (+1.26%)

Friday
Downgrade
Hookipa Pharma downgraded to Underperform from Buy at BofA » 11:59
12/02/22
12/02
11:59
12/02/22
11:59
HOOK

Hookipa Pharma

$1.02 /

+0.0295 (+2.98%)

, RHHBY

Roche

$41.14 /

+0.22 (+0.54%)

BofA analyst Alec…

BofA analyst Alec Stranahan downgraded Hookipa Pharma (HOOK) to Underperform from Buy with a price target of $0.50, down from $6. While the recent strategic collaboration and license agreement with Roche (RHHBY) offers "a stroke of confidence," it is still early innings for the partnered pipeline assets, said Stranahan. The below-expectation HB-200 monotherapy data creates a "challenging setup" going into Keytruda combo data due in the first half and he is "bearish" on upcoming catalysts to reverse sentiment, the analyst tells investors.

ShowHide Related Items >><<
RHHBY Roche
$41.14 /

+0.22 (+0.54%)

HOOK Hookipa Pharma
$1.02 /

+0.0295 (+2.98%)

HOOK Hookipa Pharma
$1.02 /

+0.0295 (+2.98%)

08/23/22 Truist
Hookipa Pharma price target lowered to $11 from $16 at Truist
02/17/22 H.C. Wainwright
Hookipa Pharma price target lowered to $8 from $15 at H.C. Wainwright
02/16/22 Truist
Hookipa Pharma price target lowered to $16 from $23 at Truist
12/22/21 Kempen
Hookipa Pharma downgraded to Neutral from Buy at Kempen
RHHBY Roche
$41.14 /

+0.22 (+0.54%)

11/29/22 Guggenheim
Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim
11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
RHHBY Roche
$41.14 /

+0.22 (+0.54%)

HOOK Hookipa Pharma
$1.02 /

+0.0295 (+2.98%)

  • 02
    Mar
RHHBY Roche
$41.14 /

+0.22 (+0.54%)

RHHBY Roche
$41.14 /

+0.22 (+0.54%)

HOOK Hookipa Pharma
$1.02 /

+0.0295 (+2.98%)

Recommendations
Anavex price target raised to $80 from $40 at JonesTrading » 07:01
12/02/22
12/02
07:01
12/02/22
07:01
AVXL

Anavex

$8.85 /

+0.03 (+0.34%)

, ESALY

Eisai

$71.85 /

+1.75 (+2.50%)

, BIIB

Biogen

$302.00 /

-2.99 (-0.98%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy raised the firm's price target on Anavex (AVXL) to $80 from $40 and keeps a Buy rating on the shares after the company announced the Phase 2b/3 trial of oral ANAVEX2-73, or blarcamesine, for the treatment of mild cognitive impairment due to Alzheimer's disease, AD, and mild AD met the primary endpoints. In Roy's view, there is "a clear win shown by ADAS-Cog" and "markedly better safety" with Anavex's oral drug than seen with Eisai (ESALY) and Biogen's (BIIB) antibody.

ShowHide Related Items >><<
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

06/23/22 Berenberg
Anavex initiated with a Buy at Berenberg
02/02/22 Cantor Fitzgerald
Anavex price target lowered to $16 from $27 at Cantor Fitzgerald
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
12/02/22
12/02
04:55
12/02/22
04:55
ESALY

Eisai

$71.85 /

+1.75 (+2.50%)

, BIIB

Biogen

$302.00 /

-2.99 (-0.98%)

Healthcare Analysts,…

Healthcare Analysts, along with Drs. Solomon and Appleby, discuss the upcoming Clinical Trials in Alzheimer's Disease (CTAD) Meeting and Eisai and Biogen's Lecanemab in the second of two Analyst/Industry conference calls to be held on December 2.

ShowHide Related Items >><<
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

Thursday
Hot Stocks
Oncolytics receives FDA Fast Track designation for pelareorep » 07:34
12/01/22
12/01
07:34
12/01/22
07:34
ONCY

Oncolytics

$1.75 /

+0.12 (+7.36%)

, RHHBY

Roche

$40.92 /

+0.26 (+0.64%)

Oncolytics Biotech (ONCY)…

Oncolytics Biotech (ONCY) announced that the U.S. FDA has granted Fast Track designation to pelareorep in combination with Roche's (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma. This represents pelareorep's second FDA Fast Track designation.

ShowHide Related Items >><<
RHHBY Roche
$40.92 /

+0.26 (+0.64%)

ONCY Oncolytics
$1.75 /

+0.12 (+7.36%)

ONCY Oncolytics
$1.75 /

+0.12 (+7.36%)

10/06/22 Maxim
Oncolytics initiated with a Buy at Maxim
01/27/22 Canaccord
Oncolytics price target lowered to $6 from $7 at Canaccord
RHHBY Roche
$40.92 /

+0.26 (+0.64%)

11/29/22 Guggenheim
Roche bladder cancer indication withdrawal positive for Seagen, says Guggenheim
11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
RHHBY Roche
$40.92 /

+0.26 (+0.64%)

ONCY Oncolytics
$1.75 /

+0.12 (+7.36%)

RHHBY Roche
$40.92 /

+0.26 (+0.64%)

RHHBY Roche
$40.92 /

+0.26 (+0.64%)

Hot Stocks
Regeneron's fianlimab and Libtayo featured in solid tumor presentations » 07:14
12/01/22
12/01
07:14
12/01/22
07:14
REGN

Regeneron

$751.41 /

+16.46 (+2.24%)

Regeneron announced new…

Regeneron announced new and updated data across its oncology pipeline to be presented at the European Society for Medical Oncology Immuno-Oncology - ESMO IO - Congress from December 7-9 in Geneva. Presentation highlights include first clinical results and new exploratory analyses from trials investigating LAG-3 inhibitor fianlimab and/or PD-1 inhibitor Libtayo - cemiplimab - in non-small cell lung cancer, melanoma and cervical cancer. Israel Lowy, Senior VP, Translational and Clinical Sciences, Oncology at Regeneron, said: "Libtayo has already proven to be an effective immunotherapy across multiple tumor types and is poised to serve as a foundational therapy for our investigational combination approaches. Fianlimab combined with Libtayo has generated early-but-promising clinical activity in advanced melanoma and non-small cell lung cancer, demonstrating the potential of Regeneron's oncology pipeline to potentially advance the standard-of-care in various cancers." Efficacy results demonstrated an objective response rate of 27% - 4 of 15 patients -. Additionally, exploratory analyses of the naive cohort found the ORR was 50% among those who had not received any prior systemic therapy and 100% among those with tumors that had greater than or equal to 50% PD-L1 expression. Median duration of response was not reached in the naive cohort and was 5 months in the experienced cohort. Rates of greater than or equal to grade 3 adverse events were respectively 33% and 40%, while rates of serious AEs were respectively 20% and 13%. There were no treatment-related deaths reported in either cohort.

ShowHide Related Items >><<
REGN Regeneron
$751.41 /

+16.46 (+2.24%)

REGN Regeneron
$751.41 /

+16.46 (+2.24%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
REGN Regeneron
$751.41 /

+16.46 (+2.24%)

REGN Regeneron
$751.41 /

+16.46 (+2.24%)

REGN Regeneron
$751.41 /

+16.46 (+2.24%)

REGN Regeneron
$751.41 /

+16.46 (+2.24%)

Recommendations
Biogen price target raised to $295 from $220 at Atlantic Equities » 06:42
12/01/22
12/01
06:42
12/01/22
06:42
BIIB

Biogen

$304.99 /

+13.525 (+4.64%)

Atlantic Equities analyst…

Atlantic Equities analyst Steve Chesney raised the firm's price target on Biogen to $295 from $220 and keeps a Neutral rating on the shares. The analyst is "encouraged" by the lecanemab full data presentation "given the consistency of the efficacy and lack of statistical wrinkles in the reported results." That said, the jury is still out on the overall clinical meaningfulness of the results, says Chesney, who expects lingering concerns on the safety profile given recent media reports.

ShowHide Related Items >><<
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ESALY

Eisai

$70.10 /

+5.35 (+8.26%)

, BIIB

Biogen

$304.99 /

+13.525 (+4.64%)

Healthcare Analysts,…

Healthcare Analysts, along with Drs. Frank Tarazi and Friedland discuss the upcoming Clinical Trials in Alzheimer's Disease (CTAD) Meeting and Eisai and Biogen's Lecanemab in the first of two Analyst/Industry conference calls to be held on December 1.

ShowHide Related Items >><<
ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

Wednesday
Options
Early notable gainers among liquid option names on November 30th » 09:55
11/30/22
11/30
09:55
11/30/22
09:55
BIIB

Biogen

$309.62 /

+18.155 (+6.23%)

, STT

State Street

$78.46 /

+4.5 (+6.08%)

, ENPH

Enphase Energy

$311.00 /

+7.445 (+2.45%)

, EPAM

Epam Systems

$350.09 /

+6.45 (+1.88%)

, LVS

Las Vegas Sands

$45.55 /

+0.89 (+1.99%)

Notable gainers among…

Notable gainers among liquid option names this morning include Biogen (BIIB) $308.85 +17.44, State Street (STT) $78.09 +4.16, Enphase Energy (ENPH) $312.25 +8.86, EPAM Systems (EPAM) $353.92 +9.98, and Las Vegas Sands (LVS) $45.93 +1.27.

ShowHide Related Items >><<
STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
STT State Street
$78.46 /

+4.5 (+6.08%)

11/15/22 Deutsche Bank
State Street price target raised to $77 from $66 at Deutsche Bank
10/19/22 Deutsche Bank
Deutsche Bank downgrades Northern Trust to Hold after Q3 results
10/12/22 Deutsche Bank
State Street price target lowered to $66 from $70 at Deutsche Bank
09/27/22 Deutsche Bank
State Street price target lowered to $70 from $74 at Deutsche Bank
ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

11/14/22 Deutsche Bank
Enphase Energy initiated with a Buy at Deutsche Bank
11/08/22 B. Riley
SolarEdge price target lowered to $370 from $377 at B. Riley
11/08/22 BMO Capital
SolarEdge price target raised to $316 from $306 at BMO Capital
10/26/22 B. Riley
Enphase Energy price target raised to $242 from $217 at B. Riley
EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

11/06/22 Barclays
Epam Systems price target lowered to $400 from $485 at Barclays
11/04/22 Citi
Epam Systems price target lowered to $400 from $520 at Citi
10/21/22 Piper Sandler
Epam Systems price target lowered to $419 from $460 at Piper Sandler
10/14/22 JPMorgan
Epam Systems price target lowered to $420 from $550 at JPMorgan
LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

11/28/22 Jefferies
Macau concession renewals removes overhang for incumbents, says Jefferies
11/28/22 JPMorgan
Las Vegas Sands price target raised to $51 from $44 at JPMorgan
11/24/22 CICC
Las Vegas Sands initiated with an Outperform at CICC
11/21/22 Morgan Stanley
Las Vegas Sands initiated with an Overweight at Morgan Stanley
STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

On The Fly
Fly Intel: Pre-market Movers » 09:00
11/30/22
11/30
09:00
11/30/22
09:00
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

, HZNP

Horizon Therapeutics

$78.78 /

+0.69 (+0.88%)

, WOOF

Petco

$9.48 /

-0.185 (-1.92%)

, TITN

Titan Machinery

$34.89 /

-0.52 (-1.47%)

, DCI

Donaldson

$59.28 /

-0.44 (-0.74%)

, ENB

Enbridge

$40.86 /

-0.34 (-0.83%)

, BBW

Build-A-Bear

$19.36 /

+0.54 (+2.87%)

, XPEV

XPeng

$7.35 /

+0.44 (+6.37%)

, WDAY

Workday

$143.37 /

-1.98 (-1.36%)

, LESL

Leslie's

$15.07 /

+0.47 (+3.22%)

, HRL

Hormel Foods

$48.17 /

-0.945 (-1.92%)

, CRWD

Crowdstrike

$137.99 /

-1.6 (-1.15%)

, ASTS

AST SpaceMobile

$6.35 /

-0.01 (-0.16%)

, JNJ

Johnson & Johnson

$176.04 /

-1.26 (-0.71%)

, AMGN

Amgen

$282.00 /

-0.67 (-0.24%)

, SNY

Sanofi

$45.89 /

+0.33 (+0.72%)

, ESALY

Eisai

$64.75 /

-0.35 (-0.54%)

Check out this morning's…

ShowHide Related Items >><<
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

DCI Donaldson
$59.28 /

-0.44 (-0.74%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

11/30/22 Cowen
Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
10/25/22 Piper Sandler
Horizon Therapeutics price target lowered to $88 from $90 at Piper Sandler
WOOF Petco
$9.48 /

-0.185 (-1.92%)

11/28/22 Wedbush
Black Friday winners Include Best Buy, losers include Pets, says Wedbush
11/28/22 Needham
Petco price target lowered to $20 from $30 at Needham
10/31/22 Citi
Petco price target lowered to $15 from $19 at Citi
10/21/22 Jefferies
Petco transferred with a Hold at Jefferies
TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

08/25/22 Baird
Titan Machinery price target raised to $34 from $27 at Baird
07/11/22 Baird
Baird trims Titan Machinery price target to $27, but 'likes' Heartland Ag deal
05/27/22 Stephens
Titan Machinery price target lowered to $41 from $44 at Stephens
05/26/22 Baird
Titan Machinery price target raised to $32 from $30 at Baird
DCI Donaldson
$59.28 /

-0.44 (-0.74%)

09/01/22 Baird
Donaldson price target lowered to $59 from $61 at Baird
07/18/22 Stifel
Donaldson price target lowered to $51 from $53 at Stifel
06/02/22 Baird
Donaldson price target lowered to $61 from $65 at Baird
03/03/22 Baird
Donaldson price target lowered to $65 from $70 at Baird
ENB Enbridge
$40.86 /

-0.34 (-0.83%)

11/07/22 National Bank
Enbridge downgraded to Sector Perform from Outperform at National Bank
10/20/22 Scotiabank
Enbridge price target lowered to C$56 from C$62 at Scotiabank
10/19/22 Morgan Stanley
Enbridge price target lowered to C$64 from C$67 at Morgan Stanley
09/12/22 Raymond James
Enbridge upgraded to Outperform from Market Perform at Raymond James
BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

11/28/22 Jefferies
XPeng downgraded to Underperform at Jefferies ahead of 'challenging year'
11/28/22 Jefferies
XPeng downgraded to Underperform from Hold at Jefferies
11/22/22 DBS Bank
XPeng initiated with a Buy at DBS Bank (earlier)
11/17/22 UBS
XPeng upgraded to Buy from Neutral at UBS
WDAY Workday
$143.37 /

-1.98 (-1.36%)

11/30/22 Deutsche Bank
Workday price target lowered to $215 from $230 at Deutsche Bank
11/30/22 Baird
Workday price target lowered to $223 from $235 at Baird
11/30/22 JPMorgan
Workday price target lowered to $223 from $235 at JPMorgan
11/30/22 Mizuho
Workday price target lowered to $200 from $220 at Mizuho
LESL Leslie's
$15.07 /

+0.47 (+3.22%)

11/28/22 Stifel
Leslie's price target lowered to $17 from $20 at Stifel
11/15/22 Baird
Leslie's downgraded to Neutral from Outperform at Baird
10/03/22 MKM Partners
MKM Partners starts Leslie's at Neutral, sees higher costs impact profitability
10/03/22 MKM Partners
Leslie's initiated with a Neutral at MKM Partners
HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

09/22/22 Argus
Hormel Foods price target lowered to $53 from $54 at Argus
09/02/22 Piper Sandler
Hormel Foods price target lowered to $47 from $48 at Piper Sandler
08/23/22 Stephens
Hormel Foods price target raised to $55 from $50 at Stephens
03/15/22 Goldman Sachs
Hormel Foods downgraded to Sell from Neutral at Goldman Sachs
CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

11/30/22 Needham
Crowdstrike price target lowered to $165 from $225 at Needham
11/30/22 DA Davidson
Crowdstrike price target lowered to $145 from $235 at DA Davidson
11/30/22 MKM Partners
Crowdstrike price target lowered to $190 from $200 at MKM Partners
11/30/22 Morgan Stanley
Morgan Stanley says investors should 'buy the dip' in Crowdstrike after Q3
ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

11/23/22 Deutsche Bank
AST SpaceMobile price target raised to $32 from $30 at Deutsche Bank
10/28/22 B. Riley
AST SpaceMobile initiated with a Buy at B. Riley
10/19/22 Barclays
AST SpaceMobile price target lowered to $15 from $29 at Barclays
08/17/22 Deutsche Bank
AST SpaceMobile price target lowered to $30 from $31 at Deutsche Bank
JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
AMGN Amgen
$282.00 /

-0.67 (-0.24%)

11/17/22 Credit Suisse
Amgen initiated with an Underperform at Credit Suisse
11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
11/08/22 Truist
Amgen price target raised to $280 from $266 at Truist
SNY Sanofi
$45.89 /

+0.33 (+0.72%)

11/14/22 Oppenheimer
Biogen price target raised to $315 from $300 at Oppenheimer
10/14/22 Barclays
Sanofi price target lowered to EUR 85 from EUR 105 at Barclays
10/06/22 Jefferies
Provention Bio price target raised to $15 from $10 at Jefferies
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

DCI Donaldson
$59.28 /

-0.44 (-0.74%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

  • 30
    Nov
  • 15
    Dec
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.